NL-OMON40652已完成不适用
A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Evaluate the Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Subjects - Evaluate the effect of intranasal esketamine on cognitive functioning
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99(—)
入选标准
- •1. Subject must be a man or woman, 18 to 49 years of age, inclusive.;2. Body mass index (BMI) (weight [kg]/height[m]2) between 18 and 30 kg/m2 (inclusive), and body weight not less than 45 kg.;3. Blood pressure (after the subject is supine for 5 minutes) between 90 and 140 mmHg systolic, inclusive, and no higher than 90 mmHg diastolic at Screening and predose on Day 1 of Period 1. ;4. A 12-lead ECG consistent with normal cardiac conduction and function at Screening and predose on Day 1 of Period 1, including:;a. Sinus rhythm;b. Heart rate between 45 and 90 beats per minute (bpm);c. QTc interval <= 450 milliseconds (ms) ;d. QRS interval of <110 ms;e. PR interval <200 ms;f. Morphology consistent with healthy cardiac conduction and ;function;1st degree AV block is exclusionary.;5. Comfortable with self-administration of intranasal medication and able to follow instructions provided.
排除标准
- •1. Subject has clinically significant liver or renal insufficiency; cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances. A significant primary sleep disorder is exclusionary.;2. Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening as deemed appropriate by the investigator.;3. Clinically significant abnormal physical examination, vital signs, or ECG at screening or on Day 1 of Period 1, as deemed appropriate by the investigator.;4. Anatomical or medical conditions that may impede delivery or absorption of study medication (e.g., undergone facial reconstruction, rhinoplasty, significant structural or functional abnormalities of the nose or upper airway; obstructions or mucosal lesions of the nostrils or nasal passages; undergone sinus surgery in the previous 2 years; or signs and symptoms of rhinitis predose on Day 1 in Period 1).;5. Has an abnormal or deviated nasal septum with any 1 or more of the following symptoms: blockage of 1 or both nostrils, nasal congestion (especially 1-sided), frequent nosebleeds, frequent sinus infections, and at times has facial pain, headaches, and postnasal drip.;6. ject has a current or prior diagnosis of psychosis/psychotic disorder.;7.History of drug or alcohol abuse disorder within the past 1 year of Screening, or a reason to believe a subject has such a history.
研究者
相似试验
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled, 2-Period, 2- Treatment Cross-Over Study to Evaluate the Effects of Ketamine on Resting State Functional Brain Connectivity in Major Depressive Disorder Patients who fail to respond to a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Noradrenaline Reuptake Inhibitor (SNRI)depressionNL-OMON43144Sumitomo Dainippon Pharma16
未知
2 期
A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study (I8K-MC-JPDA)Rheumatoid ArthritisJPRN-jRCT2080223586Eli Lilly Japan K.K.
进行中(未招募)
1 期
A study to determine the safety and efficacy of LY3337641 in Adult Patients with Rheumatoid ArthritisMedDRA version: 20.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2015-003289-97-PLEli Lilly and Company276
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled, 2-Way Crossover, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Danavorexton in Healthy Subjects Undergoing Opioid-Induced Respiratory DepressioNL-OMON52033Takeda16
未知
1 期
A Study of ALS-008176 in Infants Hospitalized With RSVJPRN-jRCT2080222986Janssen Pharmaceutical K.K.24
